Clinical Trial Update: Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of the rVSVΔG-SEBOV-GP vaccine against Sudan ebolavirus in healthy adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sudan Ebolavirus Disease

Drugs mentioned

• rVSVΔG-SEBOV-GP vaccine (rVSVΔG-SEBOV-GP)

Snippet

Sponsor: International AIDS Vaccine Initiative | Conditions: Ebola Sudan Virus Disease | Phase 1 | Status: COMPLETED